Skip to content
All Sections
Subscribe Now
64°F
Tuesday, August 20th 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
64°F
Tuesday, August 20th 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Olema Oncology
< Previous
1
2
Next >
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in June
May 28, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
May 15, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
May 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in May
May 01, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
March 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
February 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
December 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 28, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in November
November 01, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
October 22, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
October 17, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
October 16, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
October 12, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
October 10, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close